Sotrovimab
Based on 6 publication(s) in Google Scholar
Sotrovimab (VIR-7831) is a human IgG1κ monoclonal antibody targeting the Sarbecovirus subgenus; it is capable of neutralizing SARS-CoV-2, SARS-CoV-1, and various other coronaviruses. Sotrovimab can be used for research on COVID-19.
For research use only. We do not sell to patients.
- Purity : 96.80%
- CAS No.: 2423014-07-5
- Molecular Weight:146.463 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Sotrovimab
More-
Microbiological Assay
-
Microbiological Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
RT-PCR
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
SARS-CoV-2
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
YP_009724390.1
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized SARS-CoV-2/2019-nCoV Spike Protein (RBD, His Tag) can bind Sotrovimab. The EC50 for this effect is 1.47 ng/mL. -
Loaded Sotrovimab on AHC2 biosensor, can bind SARS-CoV-2 S1 Protein (Omicron, B.1.1.529, His, HY-P74445) with an affinity constant of 1.168E-08 M as determined in BLI assay.
Chemical Information
-
CAS No. 2423014-07-5
-
Appearance Liquid
-
Molecular Weight 146.463 kDa
-
Color Colorless to light yellow
-
SMILES
[Sotrovimab]
-
Synonyms
VIR-7831; GSK-4182136
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Emerg Microbes Infect
Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains. [Abstract]2026 Dec;15(1):2686472. PMID: 42324717
Sotrovimab purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2026 Dec;15(1):2686472. [Abstract]
Pseudovirus neutralization assays were performed on pseudoviruses carrying JN.1 spike proteins using BD55-1205, 719-14 sIgA, LY-CoV1404, COV2-2130, VIR 7831 (Sotrovimab) and BRII-196 antibodies to determine the antibody concentrations used in the antibody escape experiments. Error bars represent the standard error between two technical replicates.
Sotrovimab purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2026 Dec;15(1):2686472. [Abstract]
Pseudovirus neutralization assays were performed on pseudoviruses carrying XEC spike proteins using BD55-1205, 719-14 sIgA, LY-CoV1404, COV2-2130, VIR 7831 (Sotrovimab) and BRII-196 antibodies to determine the antibody concentrations used in the antibody escape experiments. Error bars represent the standard error between two technical replicates.
-
Int J Mol Sci
Moloney Murine Leukemia Virus-like Nanoparticles Pseudo-Typed with SARS-CoV-2 RBD for Vaccination Against COVID-19. [Abstract]2025 Jul 4;26(13):6462. PMID: 40650237 -
iScience
Longitudinal analysis of genomic mutations in SARS-CoV-2 isolates from persistent COVID-19 patient. [Abstract]2024 Mar 29;27(5):109597. PMID: 38638575
Sotrovimab purchased from MedChemExpress. Usage Cited in: iScience. 2024 Mar 29;27(5):109597. [Abstract]
Human iPS cell-derived lung organoids were infected with 0.1 MOI of isolated viruses in the presence MOI or absence of remdesivir (RDV) or sotrovimab and cultured for 4 days. Viral RNA copy number in the cell culture supernatant as measured by qPCR. The EC50 of remdesivir or sotrovimab was determined.
-
-
bioRxiv
A cocktail of SARS-CoV-2 spike stem helix domain and receptor binding domain human monoclonal antibodies prevent the emerge of viral escape mutants. [Abstract]2025 Oct 20:2025.10.16.682699. PMID: 41278696
Sotrovimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 20:2025.10.16.682699. [Abstract]
ARM-B7 mutant also exhibited high-level resistance (NT50 >100 μg/mL, >307-fold increase) to Sotrovimab, a Class III-targeting antibody.
Sotrovimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 20:2025.10.16.682699. [Abstract]
Fold-change in NT50 of ARM-B7 relative to the parental virus against Casirivimab, SC27, and Sotrovimab NAbs.
-
NAR Mol Med
Mechanism and spectrum of inhibition of viral polymerases by 2'-deoxy-2'-β-fluoro-4'-azidocytidine or azvudine. [Abstract]2025 Aug 11;2(3):ugaf029. PMID: 40900943
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Gupta A, et al; COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941-1950. [Content Brief]
[2]. Case JB, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun. 2022 Jul 2;13(1):3824. [Content Brief]
[4]. Aweda TA, et al. In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys. Eur J Nucl Med Mol Imaging. 2022 Oct 28:1–12. [Content Brief]
Hot Topics
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics Post-Viral Immune Dysregulation & Long COVID
Long COVID, also known as post-acute sequelae of COVID-19, is a multisystem disorder characterized by persistent and often severe symptoms following SARS-CoV-2 infection.
2025-10-27
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)